Actel to review stock option practices, retains independent counsel.

Actel Corporation has announced a voluntary review of its historical stock option granting practices. A special committee of independent directors has been formed to lead the review, and the company has informed the SEC. The review comes after a complaint was filed against certain officers and directors, relating to stock option practices.

Actel Corporation has announced a voluntary review of its historical stock option granting practices. The company has formed a special committee of independent directors to lead the review and has informed the Securities and Exchange Commission (SEC) about the process [1]. The review comes in response to a complaint filed against certain officers and directors, alleging improper stock option practices.

The special committee, comprising independent directors, will assess the company's historical stock option granting practices to ensure compliance with relevant laws and regulations. The committee's findings will be reported to the board of directors and the SEC. This move is part of Actel's ongoing efforts to maintain transparency and accountability in its corporate governance practices.

Actel Corporation's stock, traded under the ticker symbol XFOR, has seen fluctuations in response to this announcement. The company's stock price has been volatile, with analysts closely monitoring the developments [2]. Investors are advised to stay informed about the progress of the review and the potential implications for the company's financial health.

Actel's stock option practices have been under scrutiny following a recent purchase agreement with Lincoln Park. The company entered into a purchase agreement with Lincoln Park, which allows it to sell up to $40 million in stock [2]. This agreement, along with the ongoing review, highlights the importance of transparent and ethical business practices in the pharmaceutical industry.

References:
[1] https://investors.artivabio.com/News-and-Events/Corporate-Presentation/default.aspx
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_FWN3SQ0V6:0-x4-pharmaceuticals-enters-purchase-agreement-with-lincoln-park-sec-filing/